Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?

Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):93-94. doi: 10.1016/j.hbpd.2018.03.001. Epub 2018 Mar 8.

Authors

Hua-Yu Yang¹, Le-Jia Sun¹, Yi-Lei Mao²

Affiliations

¹ Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China.
² Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China. Electronic address: pumch-liver@hotmail.com.

PMID: 29576280
DOI: 10.1016/j.hbpd.2018.03.001

No abstract available

Publication types

Editorial

MeSH terms

Animals
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors*
B7-H1 Antigen / immunology
Carcinoma, Hepatocellular / drug therapy*
Carcinoma, Hepatocellular / immunology
Carcinoma, Hepatocellular / pathology
Humans
Liver Neoplasms / drug therapy*
Liver Neoplasms / immunology
Liver Neoplasms / pathology
Lymphocyte Depletion / methods*
Lymphocytes, Tumor-Infiltrating / drug effects*
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / pathology
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Signal Transduction / drug effects
T-Lymphocytes, Regulatory / drug effects*
T-Lymphocytes, Regulatory / immunology
T-Lymphocytes, Regulatory / pathology

Substances

Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
PDCD1 protein, human
Programmed Cell Death 1 Receptor